FDA 483 - Oxalis Labs - March 14, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Oxalis Labs, a finished drug product manufacturer in Baddi, India, was cited for significant deficiencies during an FDA inspection. The firm failed to maintain critical production and testing records, implement adequate control procedures for manufacturing process changes, and thoroughly investigate unexplained discrepancies and equipment malfunctions. Additionally, manufacturing equipment was not properly evaluated for design, cleaning, and maintenance, indicating systemic issues in quality control and record-keeping.
ID · 732aac14-eb14-4d67-b391-0957b77ae24a